Paradigm Biopharmaceuticals Limited (ASX: PAR) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Paradigm Biopharmaceuticals Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Paradigm Biopharmaceuticals Limited (ASX: PAR)
Latest News
Share Market News
Why the Bionomics share price is up 40% today
Share Market News
Paradigm share price tanks despite positive clinical trial update
Share Market News
Why the Mesoblast share price is going nuts today
Share Market News
Opthea share price lifts on clinical trial update: Is it a spec buy?
Share Gainers
Why Ausdrill, Link, Paradigm, & Village Roadshow shares raced higher today
Share Market News
Here's why the Opthea share price is up 130% today
Share Market News
Why Telix Pharmaceuticals shares are up 80% over the past year
Share Market News
Biotech speccy Paradigm is being tipped for the big time
Share Market News
Why the Next Science share price has more than tripled in 2019
Share Gainers
Paradigm Biopharmaceuticals share price higher on Ross River virus trial results
Share Gainers
Paradigm Biopharmaceuticals share price higher on iPPS update
Share Market News
Will the Paradigm share price climb higher on promising ASX update?
Frequently Asked Questions
-
No, Paradigm does not pay shareholder dividends at this time.
-
Paradigm Biopharmaceuticals Limited listed on the ASX on 19 August 2015.
PAR ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Paradigm Biopharmaceuticals Limited
Paradigm Biopharmaceuticals Ltd (ASX: PAR) is a late-stage drug development company researching drug repurposing. The company seeks to identify and transform existing molecules to develop effective treatments for conditions with limited treatment options. Currently, more than 30% of therapies approved or launched globally represent drugs approved for new indications, reformulations, or new combinations of existing drugs.
Paradigm's current commercial prospect is injectable pentosan polysulfate sodium (PPS, or brand name Zilosul®) in the treatment of osteoarthritis. PPS is FDA-approved and has a track record of treating inflammation including bladder condition cystitis and is used in the EU for preventing deep vein thrombosis. Paradigm has advanced to Phase 3 trial stage investigating PPS for osteoarthritis treatment. The company is based in Melbourne with offices in the US and Europe.
